GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » ROC (Joel Greenblatt) %

Echo Therapeutics (Echo Therapeutics) ROC (Joel Greenblatt) % : 1,858.65% (As of Sep. 2016)


View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Echo Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2016 was 1,858.65%.

The historical rank and industry rank for Echo Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ECTE's ROC (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.48
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Echo Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Echo Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Echo Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics ROC (Joel Greenblatt) % Chart

Echo Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,473.22 -1,209.30 -967.71 -1,135.26 -3,152.67

Echo Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,906.04 -1,771.23 -4,090.30 -5,070.25 1,858.65

Competitive Comparison of Echo Therapeutics's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, Echo Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Echo Therapeutics's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Echo Therapeutics's ROC (Joel Greenblatt) % falls into.



Echo Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.263) - (1.999 + 0 + 4.799)
=-6.535

Working Capital(Q: Sep. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.229) - (2.735 + 0 + 1.033)
=-3.539

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Echo Therapeutics for the quarter that ended in Sep. 2016 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2016  Q: Sep. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3.708/( ( (0.21 + max(-6.535, 0)) + (0.189 + max(-3.539, 0)) )/ 2 )
=3.708/( ( 0.21 + 0.189 )/ 2 )
=3.708/0.1995
=1,858.65 %

Note: The EBIT data used here is four times the quarterly (Sep. 2016) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Echo Therapeutics  (OTCPK:ECTE) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Echo Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Echo Therapeutics (Echo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830
Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.
Executives
Michael M Goldberg director C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman 10 percent owner 230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp 10 percent owner 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p. 10 percent owner 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright director ONE CORPORATE CENTER, RYE NY 10580
William Grieco director 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman director, officer: EXEC. CHAIRMAN AND INTERIM CEO C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney director, officer: CEO AND PRESIDENT C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker officer: CFO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines